Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness of Survodutide for Weight Loss in Adults with Obesity Without Diabetes

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment for people living with obesity who do not have type 2 diabetes. The treatment being tested is called BI 456906, also known as survodutide, and it is given as a solution for injection under the skin. The purpose of the study is to see if this treatment can help participants lose weight when combined with a reduced-calorie diet and increased physical activity.

Participants in the study will receive either the BI 456906 treatment or a placebo. The study will last for 76 weeks, during which time the effects of the treatment on body weight will be closely monitored. The main goal is to determine if BI 456906 is more effective than the placebo in helping participants achieve weight loss. The study will also look at other health factors, such as changes in waist size and blood pressure.

This trial is designed to provide valuable information about the safety and effectiveness of BI 456906 as a potential treatment for obesity. By participating, individuals will contribute to research that may lead to new ways to manage weight and improve health outcomes for people with obesity.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the study, an initial visit is scheduled. During this visit, a healthcare professional will explain the study details, including the purpose, procedures, and duration. Consent forms are reviewed and signed.

    Baseline measurements are taken, including body weight, waist circumference, and blood pressure. These measurements help establish a starting point for the study.

  2. Step 2

    Medication administration

    Participants receive the study medication, BI 456906, or a placebo. The medication is administered as a solution for injection under the skin, known as subcutaneous use.

    The dosage and frequency of the medication are determined by the study protocol. Participants are instructed on how to self-administer the injections if required.

  3. Step 3

    Diet and activity guidance

    Participants receive guidance on following a reduced-calorie diet and increasing physical activity. These lifestyle changes are part of the study to assess the medication's effectiveness in conjunction with these efforts.

  4. Step 4

    Regular follow-up visits

    Regular follow-up visits are scheduled throughout the 76-week study period. During these visits, healthcare professionals monitor progress, collect data, and address any concerns.

    Measurements such as body weight, waist circumference, and blood pressure are repeated to track changes over time.

  5. Step 5

    Final assessment

    At the end of the 76-week period, a final assessment is conducted. This includes a comprehensive evaluation of the participant's progress and any changes in health status.

    The primary goal is to determine the percentage change in body weight and assess whether a weight reduction of 5% or more has been achieved.

Who can join the trial?

9 criteria

  • Must be a male or female who is at least 18 years old at the time of signing the consent form. In some countries, you must be older if the legal age of consent is more than 18 years.
  • Must have a Body Mass Index (BMI) of 30 kg/m² or higher. BMI is a measure of body fat based on height and weight.
  • If your BMI is between 27 and 30 kg/m², you must have at least one of the following weight-related health issues:
    • Hypertension: High blood pressure, which is either measured as 140/90 mmHg or higher without medication, or controlled with medication.
    • Dyslipidaemia: Abnormal levels of lipids (fats) in the blood, requiring medication to maintain normal levels, or specific cholesterol and triglyceride levels.
    • Obstructive sleep apnoea: A condition where breathing stops and starts during sleep.
    • Cardiovascular disease (CVD): Includes heart failure, history of stroke, heart attack, coronary artery disease, or peripheral vascular disease.
    • Non-alcoholic steatohepatitis (NASH): A liver condition confirmed by a liver test within the last 6 months.
    • Must have a history of at least one self-reported unsuccessful attempt to lose weight through diet.
    • Additional criteria may apply.

Who cannot join the trial?

5 criteria

  • Participants cannot have **Type 2 Diabetes Mellitus (T2DM)**. This is a condition where the body does not use insulin properly, leading to high blood sugar levels.
  • Participants must not have a **Body Mass Index (BMI)** below 27 kg/m2. BMI is a measure of body fat based on height and weight.
  • Participants with a BMI of 27 kg/m2 or higher must have at least one weight-related health issue, such as high blood pressure or high cholesterol, but they cannot have T2DM.
  • Participants must be within the age range of 18 to 65 years old.
  • Both **male and female** participants are eligible, but they must not be part of a vulnerable population, which includes groups like pregnant women or those unable to consent.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Survodutide is a medication being studied to help people who are overweight or have obesity. It is given as an injection under the skin. The goal of using survodutide is to help people lose weight when combined with a diet that has fewer calories and more physical activity. This medication is being tested to see if it is safe and effective for people who do not have type 2 diabetes but have a high body mass index (BMI) or other weight-related health issues. The study is looking at how well survodutide works compared to not using any active medication. The hope is that survodutide will help people lose more weight than those who do not receive the active treatment.

What is already known about the treatment

Survodutide – Survodutide is administered through an injection under the skin, known as subcutaneous administration. It is currently being studied in clinical trials to assess its effectiveness and safety for people who are overweight or have obesity, but do not have type 2 diabetes. The main purpose of this medication is to help with weight loss when combined with a reduced-calorie diet and increased physical activity. Survodutide works by influencing certain pathways in the body that regulate appetite and energy use, helping to reduce body weight. It is classified as a weight management medication.

Investigated diseases

Obesity – Obesity is a condition characterized by excessive body fat accumulation that may impair health. It is typically defined by a Body Mass Index (BMI) of 30 or higher. The progression of obesity involves an increase in body weight and fat mass over time, often due to an imbalance between calorie intake and energy expenditure. As obesity progresses, it can lead to changes in body shape and size, and may contribute to the development of other health issues. The condition can affect various bodily systems, including metabolic, cardiovascular, and musculoskeletal systems. Obesity is influenced by a combination of genetic, environmental, and lifestyle factors.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-502529-17-00Protocol code1404-0038Estimated enrolment726 patientsSponsorBoehringer Ingelheim International GmbH

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.